Kankere ya prostate ke kankere ya bobedi yeo e tlwaelegilego kudu go banna lefaseng ka bophara, ka palo ya go akanyetšwa ya balwetši ba bafsa ba dimilione tše 1,276 bao ba begilwego ka 2018, yeo e emelago 7,1% ya balwetši ka moka ba kankere go banna.
Tekanyo ya mahu a kankere ya prostate le yona ke e kgolo, ka palo ya go akanyetšwa ya mahu a 37 005 lefaseng ka bophara ka 2018.
Lega go le bjalo, tekanyo ya mahu e fapana kudu go ya ka tikologo, Afrika Bodikela e na le kotsi ya bohlano e kgolo kudu ya mahu a kankere ya prostate lefaseng, gomme Nigeria e na le baagi ba bantši le ekonomi e kgolo kudu tikologong ye.
Kua Nigeria, kankere ya prostate ke kankere e tlwaelegilego kudu le e bolayago kudu go banna, ka palo e akanyetšwago ya 32.8 ya balwetši le mahu a 16.3 go banna ba 100 000.
Se ke palo ya go feta gabedi ya mahu a Amerika Leboa.
Go lemogwa ga bolwetši ka morago ga nako, methopo e lekanyeditšwego ya go hlahloba le go lemoga le go fokotšega ga go ngwalwa le go begwa ga balwetši go tlaleletša go kelo e phagamego ya mahu kua Nigeria.
Kua United States, kankere ya prostate ke sebaki sa bobedi se se tlwaelegilego kudu sa lehu la kankere go banna, ka banna ba ka bago 40 000 bao ba hwago ka baka la bolwetši bjo ngwaga o mongwe le o mongwe.
Tekanyo ya mahu a kankere ya prostate e be e dutše e fokotšega ganyenyane-ganyenyane ga e sa le go tloga mathomong a bo-1990, eupša e sa dutše e le bothata bjo bogolo bja tša maphelo.
Ka kakaretšo, kankere ya prostate ke bolwetši bjo bo bolayago, kudu-kudu mafelong ao a nago le phihlelelo e lekanyeditšwego ya tlhokomelo ya tša kalafo le methopo ya go hlahloba.
Lega go le bjalo, go lemoga le go alafa ka pela go ka kaonefatša mafelelo kudu le go fokotša tekanyo ya mahu.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Boikano: bja tša kalafo']
['Wepesaete ye e neetšwe feela bakeng sa go ruta le go nea tsebišo gomme ga e nee keletšo ya tša kalafo goba ditirelo tša tša kalafo.']
['Tsebišo yeo e neilwego ga se ya swanela go dirišwa bakeng sa go hlahloba goba go alafa bothata bja tša maphelo goba bolwetši, gomme bao ba nyakago keletšo ya tša kalafo ya motho ka noši ba swanetše go boledišana le ngaka yeo e nago le tumelelo.']
['Ka kgopelo lemoga gore netweke ya methapo yeo e tšweletšago dikarabo tša dipotšišo, ga e nepagale kudu ge go tliwa go diteng tša dinomoro. Ka mohlala, palo ya batho bao ba hweditšwego ba na le bolwetši bjo bo itšego.']
['Ka mehla nyaka keletšo ya ngaka ya gago goba mofani yo mongwe wa tlhokomelo ya tša maphelo yo a nago le bokgoni mabapi le boemo bja tša kalafo. Le ka mohla o se ke wa hlokomologa keletšo ya tša kalafo goba wa diega go e nyaka ka baka la selo seo o se badilego wepesaeteng ye. Ge e ba o nagana gore o ka ba o le boemong bja tšhoganetšo bja tša kalafo, leletša 911 goba o ye phapošing ya tšhoganetšo ya kgauswi le wena kapejana. Ga go na tswalano ya ngaka le molwetši yeo e bopšago ke wepesaete ye goba go e diriša. BioMedLib goba bašomi ba yona, goba motho le ge e le ofe yo a tsenyago letsogo wepesaeteng ye, ga ba dire ditshepišo le ge e le dife, e ka ba tše di boletšwego ka go lebanya goba tše di sa hlaloswago gabotse, mabapi le tsebišo yeo e neilwego mo goba go e diriša.']
['Go se tšee karolo: tokelo ya ngwalollo']
['Molao wa Digital Millennium Copyright wa 1998, 17 U.S.C. § 512 (DMCA) o nea baamogedi ba tokelo ya ngwalollo bao ba dumelago gore dilo tšeo di tšwelelago ka go Inthanete di tshwenyana le ditokelo tša bona ka tlase ga molao wa U.S. wa tokelo ya ngwalollo. ']
['Ge e ba o dumela ka potego gore diteng goba dilo tšeo di lego mabapi le wepesaete ya rena goba ditirelo di tshwenyana le tokelo ya gago ya go gatiša, wena (goba moemedi wa gago) o ka re romela tsebišo ya gore o kgopele gore diteng goba dilo tšeo di tlošwe goba gore o thibelwe go di fihlelela. ']
["Ditsebišo di swanetše go romelwa ka go ngwala ka emeile (lebelela karolo ya 'Kgokagano' go hwetša aterese ya emeile). "]
['DMCA e nyaka gore tsebišo ya gago ya go pharwa ga molao wa tokelo ya ngwalollo e akaretše tshedimošo ye e latelago: (1) tlhaloso ya mošomo wa tokelo ya ngwalollo wo o pharwago ka molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa go pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa go pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao wa pharwa ga molao.']
['(5) setatamente sa gago, seo se saennwego ka tlase ga kotlo ya go bolela maaka, gore tshedimošo yeo e lego tsebišong e nepagetše le gore o na le maatla a go phethagatša ditokelo tša mongwadi tšeo go thwego di a gatakelwa; ']
['le (6) tshaeno ya kgonthe goba ya elektroniki ya mong wa tokelo ya ngwalollo goba motho yo a dumeletšwego go dira legatong la mong wa tokelo ya ngwalollo. ']
['Go palelwa ke go akaretša tshedimošo ka moka ya ka godimo go ka dira gore go šongwa ga ngongorego ya gago go diege.']
['Go Ikgokaganya']
['Re romele imeile ka kgopelo le ge e le efe goba tšhišinyo.']
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Mabapi le']
['BioMedLib e diriša dikhomphutha tše di itirago (dikhomphutha tša go ithuta ka motšhene) go tšweletša dipara tša dipotšišo le dikarabo.']
['Re thoma ka dikgatišo tša tša kalafo ya diphedi tše dimilione tše 35 tša PubMed/Medline. Le gona, matlakala a wepesaete a RefinedWeb.']
